Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

SMILE Surgery in One Eye Compared to Ray Tracing-guided LASIK Surgery in the Fellow Eye

24 de agosto de 2026 actualizado por: Edward E. Manche, Stanford University

A Prospective Randomized Comparison of SMILE Surgery to Ray Tracing-Guided LASIK Surgery

Participants will undergo LASIK surgery in one eye using ray tracing guided technology in one eye and LASIK surgery in the other eye using wavefront guided technology. We are comparing outcomes between the two technologies as measured by self reported quality of vision and quality of life outcomes using validated questionnaires before and after surgery. We will also be comparing outcomes between the two technologies including measurement of low contrast visual acuity,and best spectacle corrected visual acuity.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Descripción detallada

Sixty-two near-sighted study participants at Stanford are planned to undergo treatment in this clinical research trial.

This comparison will be made between both eyes of the same study participant following LASIK and SMILE surgery. One eye will have ray tracing-guided LASIK and their fellow eye treated with SMILE surgery. Both ray tracing-guided LASIK surgery and SMILE surgery have been found to be safe, predictable and effective when used for laser vision correction procedures. Both ray tracing-guided LASIK surgery and SMILE surgery used in this study have been approved for laser vision correction by the United States Food and Drug Administration. Standard refractive outcomes such as uncorrected visual acuity (vision without glasses or contact lenses) and best corrected visual acuity (vision with glasses or contact lenses), and intended vs. achieved postoperative refractions (the accuracy of the LASIK and SMILE procedures) will be evaluated.

Randomization:

The choice of which eye receives ray tracing-guided LASIK surgery and which eye receives SMILE surgery will be randomized (assigned at random) prior to enrollment. Participants will have one eye treated with ray tracing-guided LASIK and your other eye treated with the SMILE surgery. Participants will know which eye is being treated with ray tracing-guided LASIK and which eye will be treated with SMILE surgery. Both ray tracing-guided LASIK and SMILE surgery are FDA-approved procedures. Both procedures are being performed according to the FDA-approved labeling. Participants have a fifty percent chance of having their left eye treated with ray tracing-guided LASIK as their right eye (like making a choice by flipping a coin). Participants will undergo bilateral (both eyes at once) surgery.

Screening and Preoperative Assessment Participants will be partially screened via telephone. We will also ask participants to complete screening by coming to the clinic in person. This screening will include measurements of corneal thickness, the shape of the cornea using corneal topography (measures the shape of the front clear surface of the eye), a slit lamp examination of the eye (a microscope to magnify the cornea) and ocular and medical history.

Participants scheduled to undergo LASIK and SMILE surgery for the correction of myopia (nearsightedness) will be screened for eligibility. Eligible participants will be examined preoperatively to establish a baseline for ocular condition (the general health and glasses prescription of the eyes). Postoperatively, participants will undergo an ophthalmic evaluation (complete eye examination) at regular intervals as specified in this protocol. Re-treatments (a second operation on the same eye for residual nearsightedness, farsightedness and/or astigmatism) will not be allowed during the first twelve months of this study. If you elect to undergo a retreatment of your LASIK surgery prior to the 12-month post-operative visit, the data after the retreatment procedure will be excluded from the study analysis.

Participants eyes will be given a thorough examination at each visit. This examination will include the standard elements of a general eye exam including testing of the eye's vision, contrast acuity testing, examination with the slit lamp and the ophthalmoscope to look at the various parts of the eye and a test of the inner eye's pressure.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

62

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

    • California
      • Palo Alto, California, Estados Unidos, 94303
        • Reclutamiento
        • Byers Eye Institute
        • Investigador principal:
          • Edward E Manche, MD
        • Contacto:
          • Edward Manche E Manche, MD
          • Número de teléfono: 650-498-7020
          • Correo electrónico: cornea@stanford.edu

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

Subjects age 22 and older with healthy eyes. Nearsightedness between -1.00 diopters and -8.00 diopters.

Subjects with less than or equal to 3.00 diopters of astigmatism.

Exclusion Criteria:

Subjects under the age of 22. Subjects with excessively thin corneas. Subjects with topographic evidence of keratoconus. Subjects with ectactic eye disorders. Subjects with autoimmune diseases. Subjects who are pregnant or nursing. Subjects must have similar levels of nearsightedness in each eye. They can not be more than 1.5 diopter of difference between eyes.

Subjects with more than 3.00 diopters of astigmatism Subjects must have similar levels of astigmatism in each eye. They can not have more than 0.75 diopters of difference between eyes.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Ray tracing guided LASIK surgery
LASIK
LASIK
Comparador activo: SMILE surgery
SMILE
LASIK

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in corrected distance visual acuity
Periodo de tiempo: Three months
The primary endpoint will be the gain in lines of corrected distance visual acuity (CDVA) at the postoperative month three follow-up compared with preoperative baseline.
Three months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Change in 5 and 25% low contrast CDVA
Periodo de tiempo: Three months
Change in 5 and 25% low contrast best corrected visual acuity from preoperative to postoperative month three
Three months
Change in patient self reported quality of vision and life
Periodo de tiempo: Three months
Will compare preoperative quality of vision and quality of life as measured by the validated Patient Reported Outcomes With LASIK (PROWL) questionnaire to postoperative month three.
Three months
Corneal epithelial thickness changes
Periodo de tiempo: Three months
Measure corneal epithelial thickness maps preoperatively and compare changes at postoperative month three
Three months
Change in higher order aberrations
Periodo de tiempo: Three months
Will measure preoperative higher order aberrations using wavefront aberrometry and compare to postoperative month three measurements
Three months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

5 de agosto de 2026

Finalización primaria (Estimado)

31 de diciembre de 2028

Finalización del estudio (Estimado)

31 de julio de 2029

Fechas de registro del estudio

Enviado por primera vez

18 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

18 de julio de 2026

Publicado por primera vez (Actual)

23 de julio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

26 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

24 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • 79951
  • 359910 (Otro número de subvención/financiamiento: Alcon)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir